BioCryst Pharmaceuticals, Inc.
Rank #3HypergrowthBCRX · Nasdaq · Healthcare
BioCryst Pharmaceuticals, Inc. (BCRX) — Rank #3 by gross profitability (GP/assets 1.53) · ROE -58.1% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0000882796 · all metrics point-in-time as of the filing date.
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Show moreShow less
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc.
was founded in 1986 and is headquartered in Durham, North Carolina.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- biocryst.com
Price History
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
$2.07B
P/E (annual)
6.7
P/S (annual)
2.4
P/B
—
P/OCF (annual)
6.0
Shareholder Yield
-196.6%
Employees
435
Industry
Drug Manufacturers - Specialty & Generic
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 4/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
-11.7%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 196.6% — per-share value needs a total required return of 184.9% once share-count change is priced in.
vs. own 6-year median revenue growth: -13.0%
Cost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
-14.7%
r = 10% (base)
-11.7%
r = 12%
-9.0%
Net debt / market cap: 2.4%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
Disclosure regression check
2 previously-disclosed line items are no longer reported. Worth checking the filing for why.
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
1.53
Primary signal (Novy-Marx).
100th pctl of 34 SIC 28 peers
Return on equity
-58.1%
Gross margin
97.8%
97th pctl of 34 SIC 28 peers
Revenue growth (YoY)
3219.7%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2014 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
—
Current ratio
2.32×
52nd pctl of 34 SIC 28 peers
Quick ratio
2.22×
Net cash
-$42.83M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$344.90M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.31
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
9.7%
Stock-based comp intensity.
Piotroski F-Score
F-Score
8 / 9
Fundamental-strength score (0-9).
Lifecycle Phase History
Lynch sell alert: Turnaround stalled
Classified startup for 2 consecutive fiscal years (2016-12-31, 2017-12-31) with no recovery to a healthier phase -- Lynch's turnaround rule: if it hasn't turned around by now, assume it isn't going to.